RecruitingPhase 2NCT07173803
The Progressive Supranuclear Palsy Clinical Trial Platform
Sponsor
Adam Boxer
Enrollment
440 participants
Start Date
Jul 29, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
Eligibility
Min Age: 41 YearsMax Age: 86 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called AADvac1 and a drug called LM11A-31 for people with progressive supranuclear palsy (psp). The study is currently recruiting participants at 1 location. People eligible for this study include aged 41 Years to 86 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAADvac1
Active immunotherapy
DRUGLM11A-31
Small molecule
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07173803
Related Trials
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
NCT07805967
Biofluid Research on Age-Related or Inherited Neurodegeneration
NCT07798700
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT0436368427 locations
Synaptic Loss in Multiple System Atrophy
NCT051210121 location
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
NCT073924111 location